{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03982693",
            "orgStudyIdInfo": {
                "id": "19-05-H-01"
            },
            "organization": {
                "fullName": "Mt. Sinai Medical Center, Miami",
                "class": "OTHER"
            },
            "briefTitle": "Trial to Assess Chelation Therapy in Critical Limb Ischemia",
            "officialTitle": "Trial to Assess Chelation Therapy in Critical Limb Ischemia",
            "acronym": "TACT3a",
            "therapeuticArea": [
                "Critical Care",
                "Endocrinology"
            ],
            "study": "trial-to-assess-chelation-therapy-in-critical-limb-ischemia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-03-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-05-27",
            "studyFirstSubmitQcDate": "2019-06-09",
            "studyFirstPostDateStruct": {
                "date": "2019-06-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Gervasio Lamas, MD",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mt. Sinai Medical Center, Miami"
            },
            "leadSponsor": {
                "name": "Mt. Sinai Medical Center, Miami",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.",
            "detailedDescription": "TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.\n\nThe study plans to enroll 50 patients with diabetes and critical limb ischemia (CLI) to prevent the major cardiovascular endpoints of major amputation, coronary revascularization, stroke, Myocardial Infarction (MI), or death (all-cause) during an average 1.25 years of follow-up. Patients will be randomly assigned to chelation or placebo with a 3:2 (30 active, 20 placebo) allocation ratio. Treatment will consist of 40 active or placebo infusions over 30 weeks. Active therapy will be the same edetate disodium-based infusion used safely and successfully in a previous published study, Trial to Assess Chelation Therapy (TACT). Baseline and post infusion urine metals will be collected. Following the final infusion, patients will be contacted quarterly until the end of the study."
        },
        "conditionsModule": {
            "conditions": [
                "Critical Limb Ischemia",
                "Diabetes"
            ],
            "keywords": [
                "Chelation",
                "Critical Limb Ischemia",
                "Diabetes"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "maskingDescription": "double-blind",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Active",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "edetate disodium (EDTA)dff active infusion",
                    "interventionNames": [
                        "Drug: Edetate Disodium"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo infusion",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Edetate Disodium",
                    "description": "The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.",
                    "armGroupLabels": [
                        "Active"
                    ],
                    "otherNames": [
                        "TACT EDTA infusion"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Placebo infusions consist of 500 ml normal saline.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Prevention of major cardiovascular endpoints",
                    "description": "Major cardiovascular endpoints include: coronary revascularization, stroke, MI, death (all-cause), or major amputation",
                    "timeFrame": "3 years (average follow-up 1.25 years)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Amputations",
                    "description": "* Major amputations due to vascular disease. Major amputations are defined as any procedure that results in amputation at the level above the ankle. 49, 50\n* Total amputations due to vascular disease",
                    "timeFrame": "3 years (average follow-up 1.25 years)"
                },
                {
                    "measure": "Heart failure",
                    "description": "\u2022 Heart failure hospitalizations or prolonged (\\>12 hours) ER stay for heart failure",
                    "timeFrame": "3 years (average follow-up 1.25 years)"
                },
                {
                    "measure": "Changes in Pain severity",
                    "description": "\u2022 Any changes in pain will be recorded at baseline, infusions 10, 20, 40 (or final), and end of study recorded using the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference- Short Form 8a. The scale range is 1 to 5, with 1 being the best outcome (no pain interference) and 5 the worse (very much interference)",
                    "timeFrame": "3 years (average follow-up 1.25 years)"
                },
                {
                    "measure": "Urine Metals",
                    "description": "\u2022 Changes in urine metal levels measured at the Metals Core Lab and measured at baseline and infusion 40 (or final).",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Changes in Quality of Life",
                    "description": "\u2022 Health-related quality of life (QOL) changes recorded at baseline, 10, 20, 40 (or final), and end of study using the 36-Item Short Form Health Survey (SF-36 v2). The 36 questions assess eight health-related concepts: physical functioning, role limitations due to physical health problems (role physical), bodily pain, general health, energy levels/fatigue (vitality), social functioning, role limitations due to emotional problems (role emotional), and psychological distress (mental health). The scales vary depending on the question asked.The survey will be used to detect change (better or worse) in participants' health state over the course of the study.",
                    "timeFrame": "3 years (average follow-up 1.25 years)"
                },
                {
                    "measure": "Wound Severity",
                    "description": "Wound severity (quantified and imaged with HIPAA-compliant photography) photographed at baseline 10, 20, 40 (or final), and end of study",
                    "timeFrame": "3 years (average follow-up 1.25 years)"
                },
                {
                    "measure": "Changes in skin perfusion pressure in the ankle",
                    "description": "\u2022 Changes in skin perfusion pressure will be measured at 10, 20, 40 (or final), and end of study, using the ankle-brachial index (mmHg)",
                    "timeFrame": "3 years (average follow-up 1.25 years)"
                },
                {
                    "measure": "Changes in skin perfusion pressure in the toe",
                    "description": "\u2022 Changes in skin perfusion pressure will be measured at 10, 20, 40 (or final), and end of study, using the toe-brachial index (mmHg).",
                    "timeFrame": "3 years (average follow-up 1.25 years)"
                },
                {
                    "measure": "Changes in PAD Quality of Life",
                    "description": "\u2022 PAD related quality of life (QOL) changes recorded at baseline, 10, 20, 40 (or final), and end of study using the Peripheral Artery Questionnaire (PAQ), which is a 20-item questionnaire measuring physical limitations, symptoms, symptom stability, treatment satisfaction, quality of life, and social function. The scales vary depending on the question asked. The survey will be used to detect change (better or worse) in participants responses over the course of the study.",
                    "timeFrame": "3 years (average follow-up 1.25 years)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 50 years\n* History of diabetes, defined as medical record evidence or patient report of currently using insulin or oral hypoglycemic agents, or with a history of fasting blood glucose measurement of 126 mg/dL or higher, or a history of HbA1c of 6.5% or higher.\n* Significant stenosis (\u2265 75%) of two or more infra-popliteal arteries in the affected limb as verified by at least one imaging technique (angiography, magnetic resonance angiogram, coronary computed tomography angiogram, or doppler examination) within 6 months prior to enrollment;\n* History of CLI defined as moderate or high-risk infra-popliteal chronic critical limb ischemia (Rutherford Clinical Severity Score 4 or 5) defined as:\n\n  * The presence of rest pain or non-healing ulceration or gangrene for at least 2 weeks plus documentation of severely compromised tissue perfusion:\n  * If there is tissue loss, a resting ankle systolic pressure of \u2264 60 mmHg in the affected limb; or a resting toe systolic pressure of \u2264 40 mmHg or a tissue perfusion pressure (TPP) \\<40 mmHg.\n  * If there is no tissue loss, a resting ankle pressure of \u2264 50 mmHg or resting toe systolic pressure of \u2264 30 mmHg or a tissue perfusion pressure (TPP) \\< 30 mmHg.\n* Not a candidate or a failed candidate for surgical or transcatheter revascularization;\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* \\<7 days following lower extremity (infra-popliteal), carotid, or coronary revascularization.\n* Arterial insufficiency in the lower extremity as the result of a non-atherosclerotic disorder.\n* Subjects with evidence of active infection (e.g., cellulitis, osteomyelitis) or deep ulceration exposing bone or tendon or extensive heel ulceration\n* Subjects with extensive gangrene extending above the MT joint\n* Subjects in whom there is severe pain at rest uncontrollable with pain medications\n* Prior intravenous chelation therapy consisting of \\> 1 infusion within 5 years; if only 1 infusion took place, patient cannot be enrolled for at least 12 months after said infusion.\n* Oral chelation with an FDA-approved chelating agent within 2 years\n* Allergy to any components of the study drug\n* Planned leg revascularization within 1 month of enrollment\n* Symptomatic or clinically evident acute heart failure\n* Heart failure hospitalization within 3 months\n* Blood pressure \\>160/100\n* No venous access\n* eGFR \\< 30 mL/min per 1.73 m2 or lower (CKD stages 1-3) calculated with MDRD\n* Known or suspected acute kidney injury using prevalent KDIGO criteria45\n* Platelet count \\<100,000/mm3\n* Cigarette smoking within the last 3 months\n* Liver disease or Alanine aminotransferase (ALT), aspartate aminotransferase (AST) \\> 2.0 times the upper limit of normal (this will require clearance by the Study PI)\n* Diseases of copper, iron, or calcium metabolism (other than osteopenia or osteoporosis, or simple iron deficiency). These require evaluation by the Study PI\n* Inability to tolerate the study-required fluid load\n* Other medical condition likely to affect patient survival within 3 years\n* Women of child-bearing potential\n* Any factor that suggests that the potential participant will not be able to adhere to the protocol.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "50 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Francisco Ujueta, MD",
                    "role": "CONTACT",
                    "phone": "305-674-2162",
                    "email": "Francisco.Ujueta@msmc.com"
                },
                {
                    "name": "Beatriz Acevedo",
                    "role": "CONTACT",
                    "phone": "305-674-2162",
                    "email": "Beatriz.Acevedo@msmc.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gervasio Lamas, MD",
                    "affiliation": "Icahn School of Medicine at Mount Sinai",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mount Sinai Medical Center",
                    "status": "RECRUITING",
                    "city": "Miami Beach",
                    "state": "Florida",
                    "zip": "33140",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Francisco Ujueta, MD",
                            "role": "CONTACT",
                            "phone": "305-674-2162",
                            "email": "Francisco.Ujueta@msmc.com"
                        },
                        {
                            "name": "Beatriz Acevedo",
                            "role": "CONTACT",
                            "phone": "305-674-2162",
                            "email": "Beatriz.Acevedo@msmc.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.79065,
                        "lon": -80.13005
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "28689036",
                    "type": "BACKGROUND",
                    "citation": "Arenas IA, Navas-Acien A, Ergui I, Lamas GA. Enhanced vasculotoxic metal excretion in post-myocardial infarction patients following a single edetate disodium-based infusion. Environ Res. 2017 Oct;158:443-449. doi: 10.1016/j.envres.2017.06.039. Epub 2017 Jul 6."
                },
                {
                    "pmid": "22172430",
                    "type": "BACKGROUND",
                    "citation": "Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J. 2012 Jan;163(1):7-12. doi: 10.1016/j.ahj.2011.10.002."
                },
                {
                    "pmid": "24254885",
                    "type": "BACKGROUND",
                    "citation": "Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, Nahas R, Lewis EF, Lindblad L, Lee KL. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):15-24. doi: 10.1161/CIRCOUTCOMES.113.000663. Epub 2013 Nov 19."
                },
                {
                    "pmid": "30152247",
                    "type": "BACKGROUND",
                    "citation": "Ujueta F, Arenas IA, Diaz D, Yates T, Beasley R, Navas-Acien A, Lamas GA. Cadmium level and severity of peripheral artery disease in patients with coronary artery disease. Eur J Prev Cardiol. 2019 Sep;26(13):1456-1458. doi: 10.1177/2047487318796585. Epub 2018 Aug 28. No abstract available."
                },
                {
                    "pmid": "31101487",
                    "type": "BACKGROUND",
                    "citation": "Ujueta F, Arenas IA, Escolar E, Diaz D, Boineau R, Mark DB, Golden P, Lindblad L, Kim H, Lee KL, Lamas GA. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT). J Diabetes Complications. 2019 Jul;33(7):490-494. doi: 10.1016/j.jdiacomp.2019.04.005. Epub 2019 Apr 14."
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000089802",
                    "term": "Chronic Limb-Threatening Ischemia"
                },
                {
                    "id": "D000007511",
                    "term": "Ischemia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000058729",
                    "term": "Peripheral Arterial Disease"
                },
                {
                    "id": "D000050197",
                    "term": "Atherosclerosis"
                },
                {
                    "id": "D000001161",
                    "term": "Arteriosclerosis"
                },
                {
                    "id": "D000001157",
                    "term": "Arterial Occlusive Diseases"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000016491",
                    "term": "Peripheral Vascular Diseases"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10543",
                    "name": "Ischemia",
                    "asFound": "Ischemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "relevance": "LOW"
                },
                {
                    "id": "M2714",
                    "name": "Chronic Limb-Threatening Ischemia",
                    "asFound": "Critical Limb Ischemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M29213",
                    "name": "Peripheral Arterial Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M18894",
                    "name": "Peripheral Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M26188",
                    "name": "Atherosclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4469",
                    "name": "Arteriosclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4465",
                    "name": "Arterial Occlusive Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000004492",
                    "term": "Edetic Acid"
                },
                {
                    "id": "D000004369",
                    "term": "Pentetic Acid"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000925",
                    "term": "Anticoagulants"
                },
                {
                    "id": "D000065096",
                    "term": "Calcium Chelating Agents"
                },
                {
                    "id": "D000002614",
                    "term": "Chelating Agents"
                },
                {
                    "id": "D000064449",
                    "term": "Sequestering Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000931",
                    "term": "Antidotes"
                },
                {
                    "id": "D000020011",
                    "term": "Protective Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000007502",
                    "term": "Iron Chelating Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7662",
                    "name": "Edetic Acid",
                    "asFound": "Non-proliferative Diabetic Retinopathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M23026",
                    "name": "Vitamin B 6",
                    "relevance": "LOW"
                },
                {
                    "id": "M14583",
                    "name": "Pyridoxal",
                    "relevance": "LOW"
                },
                {
                    "id": "M14589",
                    "name": "Pyridoxine",
                    "relevance": "LOW"
                },
                {
                    "id": "M9579",
                    "name": "Heparin",
                    "relevance": "LOW"
                },
                {
                    "id": "M46053",
                    "name": "Calcium heparin",
                    "relevance": "LOW"
                },
                {
                    "id": "M7543",
                    "name": "Pentetic Acid",
                    "asFound": "Respiratory acidosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13124",
                    "name": "Pantothenic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M16595",
                    "name": "Thiamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M14216",
                    "name": "Procaine",
                    "relevance": "LOW"
                },
                {
                    "id": "M4244",
                    "name": "Anticoagulants",
                    "relevance": "LOW"
                },
                {
                    "id": "M5381",
                    "name": "Calcium",
                    "relevance": "LOW"
                },
                {
                    "id": "M5398",
                    "name": "Calcium, Dietary",
                    "relevance": "LOW"
                },
                {
                    "id": "M5860",
                    "name": "Chelating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4250",
                    "name": "Antidotes",
                    "relevance": "LOW"
                },
                {
                    "id": "M21869",
                    "name": "Protective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10533",
                    "name": "Iron",
                    "relevance": "LOW"
                },
                {
                    "id": "M10534",
                    "name": "Iron Chelating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "T474",
                    "name": "Vitamin B6",
                    "relevance": "LOW"
                },
                {
                    "id": "T459",
                    "name": "Pyridoxal",
                    "relevance": "LOW"
                },
                {
                    "id": "T461",
                    "name": "Pyridoxine",
                    "relevance": "LOW"
                },
                {
                    "id": "T472",
                    "name": "Vitamin B5",
                    "relevance": "LOW"
                },
                {
                    "id": "T464",
                    "name": "Thiamin",
                    "relevance": "LOW"
                },
                {
                    "id": "T465",
                    "name": "Thiamine",
                    "relevance": "LOW"
                },
                {
                    "id": "T469",
                    "name": "Vitamin B1",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnCoag",
                    "name": "Anticoagulants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "FiAg",
                    "name": "Fibrinolytic Agents"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "BDCA",
                    "name": "Bone Density Conservation Agents"
                },
                {
                    "abbrev": "Vi",
                    "name": "Vitamins"
                }
            ]
        }
    },
    "hasResults": false
}